BIOGATE PRECISION MEDICINE CORP.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
BIOGATE PRECISION MEDICINE CORP. has independently developed a specialized carrier protein that can effectively enhance the responsiveness of B cells to antigens (including autoantigens), thereby producing antibody drugs with high affinity and high specificity. The innovative design of this carrier protein successfully resolves the issue of low immunogenicity of autoantigens, significantly improving the efficiency and specificity of antibody production, while enhancing therapeutic efficacy and safety, to provide clinical applications with more precise and effective antibody drugs.
The content above was translated by Ai
Founded Year
2015
Unified Business No.
24939569
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,880,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Founded in 2015, Zhihe upholds the core philosophy of precision medicine, "Right Target, Right Drug, Right Patient, Right Time," and is committed to the independent research and development of first-in-class novel cancer antibody drugs. Through the brand-new and unique mechanisms of action of innovative targets, Zhihe hopes to provide highly specific and exceptionally efficacious therapeutic solutions for the right patients at the optimal time.
Utilizing innovative technology, Zhihe can efficiently screen for suitable therapeutic targets and produce highly potential antibody drugs through its novel antibody technology platform. By further combining this with advanced biomarker technology, Zhihe provides precise therapies for cancer patients at critical moments in their disease progression, thereby enhancing treatment efficacy and improving the patients' quality of life.
Utilizing innovative technology, Zhihe can efficiently screen for suitable therapeutic targets and produce highly potential antibody drugs through its novel antibody technology platform. By further combining this with advanced biomarker technology, Zhihe provides precise therapies for cancer patients at critical moments in their disease progression, thereby enhancing treatment efficacy and improving the patients' quality of life.
The content above was translated by Ai
